Taysha Gene Therapies (TSHA) Cash & Equivalents (2020 - 2026)

Taysha Gene Therapies has disclosed Cash & Equivalents across 7 years of filings, most recently posting $276.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $276.6 million, up 137.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $276.6 million (up 137.21% YoY), and the FY2025 annual result was $319.8 million, up 131.21% from the prior year.
• Cash & Equivalents came in at $276.6 million for Q1 2026 at Taysha Gene Therapies, down from $319.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $319.8 million in Q4 2025 to a low of $34.3 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $140.4 million (2023), against an average of $158.3 million.
• Across the five-year window, Cash & Equivalents tumbled 81.83% in 2022 and surged 378.86% in 2023, its largest moves.
• Taysha Gene Therapies' Cash & Equivalents stood at $34.3 million in 2022, then jumped by 315.09% to $142.4 million in 2023, then slipped by 2.88% to $138.3 million in 2024, then soared by 131.21% to $319.8 million in 2025, then dropped by 13.51% to $276.6 million in 2026.
• The last three Cash & Equivalents figures came in at $276.6 million (Q1 2026), $319.8 million (Q4 2025), and $297.3 million (Q3 2025), per Business Quant data.